

*Contact Person For More Information:*  
Wendy Vance, HICPAC, Division of  
Healthcare Quality Promotion, NCPDCID,  
CDC, 1600 Clifton Road, NE., Mailstop D-10,  
Atlanta, Georgia 30333 Telephone (404) 639-  
2891 or [HICPAC@cdc.gov](mailto:HICPAC@cdc.gov).

The Director, Management Analysis and  
Services Office, has been delegated the  
authority to sign **Federal Register** notices  
pertaining to announcements of meetings and  
other committee management activities, for  
both CDC and the Agency for Toxic  
Substances and Disease Registry.

Dated: July 17, 2009.

**Elaine L. Baker,**

*Director, Management Analysis and Services  
Office, Centers for Disease Control and  
Prevention (CDC).*

[FR Doc. E9-17514 Filed 7-21-09; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2009-N-0302]

#### Withdrawal of Approval of New Animal Drug Applications; Ketamine; S- Methoprene; Nitazoxanide

**AGENCY:** Food and Drug Administration,  
HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug  
Administration (FDA) is withdrawing  
approval of two new animal drug  
applications (NADAs) and an  
abbreviated new animal drug  
application (ANADA) listed in table 1 of  
this document. In a final rule published

elsewhere in this issue of the **Federal  
Register**, FDA is amending the animal  
drug regulations to remove portions  
reflecting approval of these NADAs and  
ANADA.

**DATES:** Withdrawal of approval is  
effective August 3, 2009.

**FOR FURTHER INFORMATION CONTACT:** John  
Bartkowiak, Center for Veterinary  
Medicine (HFV-212), Food and Drug  
Administration, 7519 Standish Pl.,  
Rockville, MD 20855, 240-276-9079, e-  
mail: [john.bartkowiak@fda.hhs.gov](mailto:john.bartkowiak@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The  
following sponsors have requested that  
FDA withdraw approval of the two  
NADAs and ANADA listed in table 1 of  
this document because the products are  
no longer manufactured or marketed:

TABLE 1.

| Sponsor  | NADA/ANADA Number<br>Product (Drug)                      | 21 CFR Cite Affected<br>(Sponsor Drug Labeler Code) |
|--|--|---|
| Wellmark International, 1501 East Woodfield<br>Rd., suite 200, West Schaumburg, IL 60173 | NADA 141-162<br>Zodiac Fleatrol Flea Caps (S-methoprene) | 520.1390 (011536)                                   |
| IDEXX Pharmaceuticals, Inc., 7009 Albert<br>Pick Rd., Greensboro, NC 27409               | NADA 141-178<br>NAVIGATOR Paste (nitazoxanide)           | 520.1498 (065274)                                   |
| Abbott Laboratories, North Chicago, IL 60064   | ANADA 200-279<br>KETAFLO Injection (ketamine HCl, USP)   | 522.1222a (000074)                                  |

Therefore, under authority delegated  
to the Commissioner of Food and Drugs  
and redelegated to the Center for  
Veterinary Medicine, and in accordance  
with § 514.116 *Notice of withdrawal of  
approval of application* (21 CFR  
514.116), notice is given that approval  
of NADAs 141-162 and 141-178, and  
ANADA 200-279, and all supplements  
and amendments thereto, are hereby  
withdrawn, effective August 3, 2009.

In a final rule published elsewhere in  
this issue of the **Federal Register**, FDA  
is amending the animal drug regulations  
to reflect the withdrawal of approval of  
these NADAs.

Dated: July 14, 2009.

**Bernadette Dunham,**

*Director, Center for Veterinary Medicine.*

[FR Doc. E9-17408 Filed 7-21-09; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HOMELAND SECURITY

### Federal Emergency Management Agency

[Docket ID: FEMA-2009-0001]

#### Agency Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:** Federal Emergency  
Management Agency, DHS.

**ACTION:** Notice; 60-day notice and  
request for comments; revision of a  
currently approved information  
collection; OMB No. 1660-0095; No  
Form.

**SUMMARY:** The Federal Emergency  
Management Agency, as part of its  
continuing effort to reduce paperwork  
and respondent burden, invites the  
general public and other Federal  
agencies to take this opportunity to  
comment on a proposed revision of a  
currently approved information  
collection. In accordance with the  
Paperwork Reduction Act of 1995, this  
Notice seeks comments concerning the  
process for the appeal of decisions of  
flood insurance claims issued through  
the National Flood Insurance Program

(NFIP). The appeal process establishes a  
formal mechanism to allow  
policyholders to appeal the decisions of  
any insurance agent, adjuster, insurance  
company, or any FEMA employee or  
contractor, in cases or unsatisfactory  
decisions on claims, proof of loss, and  
loss estimates.

**DATES:** Comments must be submitted on  
or before September 21, 2009.

**ADDRESSES:** To avoid duplicate  
submissions to the docket, please use  
only one of the following means to  
submit comments:

(1) *Online.* Submit comments at  
<http://www.regulations.gov> under  
docket ID FEMA-2009-0001. Follow the  
instructions for submitting comments.

(2) *Mail.* Submit written comments to  
Office of Chief Counsel, Regulation and  
Policy Team, DHS/FEMA, 500 C Street,  
SW., Room 835, Washington, DC 20472-  
3100.

(3) *Facsimile.* Submit comments to  
(703) 483-2999.

(4) *E-mail.* Submit comments to  
[FEMA-POLICY@dhs.gov](mailto:FEMA-POLICY@dhs.gov). Include docket  
ID FEMA-2009-0001 in the subject line.

All submissions received must  
include the agency name and docket ID.  
Regardless of the method used for  
submitting comments or material, all  
submissions will be posted, without